Anatara Lifesciences is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Our lead product Detach™ is a natural product that will help address global concerns around the overuse of antibiotics in animals and their feed that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Latest news All news
Trial Results Support Strong Partnering Interest
Anatara Lifesciences is pleased to release its market update presentation. Executives of the company will be presenting to brokers, analysts and institutional investors over the next two weeks on the company’s progress and track record in delivering against key milestones.
Please click here to view the ASX announcement and investor presentation.
Wilson HTM has released its second research and valuation report on Anatara Lifesciences (ANR). The report provided a Speculative BUY rating and a price target at $1.18 per share.
Please open the attached PDF to view the report.